Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by HighSkies2019on Sep 03, 2021 6:49pm
327 Views
Post# 33813575

Matter Of Time !!!

Matter Of Time !!!This is IMO ... yes I am thinking that is a delay for our GVHD to still be in our possession....a drug that was close to market by us ... Certainly Bob would like his return on that as well I would think.....he's not a talent holder ....we know the world is in desperate need for anything safe to void of the virus and mutations ... we all have read different literatures about the NO molecule support to stop the virus...so I can't see us sitting much longer to see what our truth is ....Bob could have walked away he didn't...he put together a deal ...a collection of collaborators...everything we know was publicized in news releases ... as Bob said he spoke to many suggested offers on the GVHD but none he felt was worth the value of our GVHD ...now he has R107 NO that covers multiple billion dollar markets... GVHD billion dollar market...Pain billion dollar market ...yes hoping Bob did get a great deal for us all ....and the way everything is rolling out leads me towards a buyout....my thoughts for the week end .... gltal
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities